Google
Apple
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
SQZ BIOT |
Market Closed -
Other stock markets
|
|
5-day change | 1st Jan Change | |
| 0.03 USD | +46.34% | +62.16% | -95.95% | |
| Nov. 08 | SQZ Biotechnologies Company Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 | CI |
| Nov. 08 | SQZ Biotechnologies Company Contemplates Bankruptcy. | CI |
Financials (USD)
| Sales 2023 * | 200K | Sales 2024 * | - | Capitalization | 885K |
|---|---|---|---|---|---|
| Net income 2023 * | -71M | Net income 2024 * | -67M | EV / Sales 2023 * | 4,42x |
| Net cash position 2023 * | - | Net cash position 2024 * | - | EV / Sales 2024 * | - |
| P/E ratio 2023 * | - | P/E ratio 2024 * | - | Employees | 53 |
| Yield 2023 * | - | Yield 2024 * | - | Free-Float | 99.69% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | +46.34% | ||
| 1 week | +62.16% | ||
| Current month | +22.45% | ||
| 1 month | -39.64% | ||
| 3 months | -47.37% | ||
| 6 months | -94.52% | ||
| Current year | -95.95% |
1 week
0.02
0.03
1 month
0.010.06
Current year
0.011.01
1 year
0.011.29
3 years
0.0135.17
5 years
0.0136.49
10 years
0.0136.49
| Managers | Title | Age | Since |
|---|---|---|---|
Howard Bernstein
CEO | Chief Executive Officer | 66 | 2015 |
Marshelle Warren
CTO | Chief Tech/Sci/R&D Officer | - | 2022 |
Michael Kaiser
IRC | Investor Relations Contact | - | 2021 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Amy Schulman
CHM | Chairman | 62 | 2015 |
Howard Bernstein
CEO | Chief Executive Officer | 66 | 2015 |
Sapna Srivastava
BRD | Director/Board Member | 52 | 2020 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 281,588 M€ | +18.18% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23-12-06 | 0.03 | +46.34% | 96,279 |
| 23-12-05 | 0.0205 | -2.38% | 14,528 |
| 23-12-04 | 0.021 | -10.26% | 25,858 |
| 23-12-01 | 0.0234 | -4.49% | 61,700 |
| 23-11-30 | 0.0245 | +32.43% | 201,671 |
Delayed Quote OTC Markets, December 06, 2023 at 03:20 pm EST
More quotes
SQZ Biotechnologies Company is a clinical-stage biotechnology company. The Company is focused on unlocking the full potential of cell therapies to benefit patients. In oncology, it is developing cell therapy platforms that are based on directing tumor antigen-specific immune activation via engineered antigen presentation. Its clinical-stage cell therapy candidates include SQZ Enhanced APC (eAPC) Platform, SQZ Activating Antigen Carrier (AAC) Platform and SQZ Tolerizing Antigen Carrier (TAC) Platform. The SQZ eAPC platform is the second-generation product candidate designed to generate tumor specific CD8+ T cell activation to drive the antitumor immune response. The SQZ AAC platform is designed to induce antigen presentation in vivo by deriving antigen carriers from engineering red blood cells (RBCs) with tumor specific antigens and adjuvants. Its SQZ TAC platform is designed to induce antigen-specific immune tolerance in vivo by utilizing a similar approach to the AAC platform.
Calendar
2024-03-13
- Q4 2023 Earnings Release (Projected)
Trading Rating :
Investor Rating :
ESG Refinitiv :
D+
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
0.03
Average target price
-
Spread / Average Target
-100.00%
| 1st Jan change | Capi. | |
|---|---|---|
| -95.95% | 884 733 $ | |
| +67.92% | 40 713 M $ | |
| +5.22% | 39 345 M $ | |
| -55.13% | 30 731 M $ | |
| -27.61% | 28 435 M $ | |
| +38.19% | 22 100 M $ | |
| -26.35% | 21 964 M $ | |
| -0.25% | 16 910 M $ | |
| -13.70% | 11 278 M $ | |
| -20.32% | 10 444 M $ |
